Switch theme
Sign up to access all valuation multiples
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
2002
6
LTM Revenue n/a
LTM EBITDA n/a
$32.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharma Equity Group has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pharma Equity Group achieved revenue of n/a and an EBITDA of -$3.5M.
Pharma Equity Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharma Equity Group valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | $0.6M | -$3.5M | n/a | n/a | XXX |
| EBITDA Margin | Infinity% | -Infinity% | NaN% | NaN% | XXX |
| Net Profit | $0.8M | $0.5M | -$3.4M | XXX | XXX |
| Net Margin | Infinity% | Infinity% | NaN% | XXX | XXX |
| Net Debt | $2.6M | $3.2M | $3.6M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Pharma Equity Group's stock price is DKK 0 (or $0).
Pharma Equity Group has current market cap of DKK 184M (or $25.7M), and EV of DKK 233M (or $32.6M).
See Pharma Equity Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32.6M | $25.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Pharma Equity Group has market cap of $25.7M and EV of $32.6M.
Pharma Equity Group's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Pharma Equity Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pharma Equity Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $32.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharma Equity Group's NTM/LTM revenue growth is Infinity%
Pharma Equity Group's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Pharma Equity Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pharma Equity Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pharma Equity Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharma Equity Group acquired XXX companies to date.
Last acquisition by Pharma Equity Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharma Equity Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pharma Equity Group founded? | Pharma Equity Group was founded in 2002. |
| Where is Pharma Equity Group headquartered? | Pharma Equity Group is headquartered in Denmark. |
| How many employees does Pharma Equity Group have? | As of today, Pharma Equity Group has 6 employees. |
| Is Pharma Equity Group publicy listed? | Yes, Pharma Equity Group is a public company listed on CSE. |
| What is the stock symbol of Pharma Equity Group? | Pharma Equity Group trades under PEG ticker. |
| When did Pharma Equity Group go public? | Pharma Equity Group went public in 2003. |
| Who are competitors of Pharma Equity Group? | Similar companies to Pharma Equity Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pharma Equity Group? | Pharma Equity Group's current market cap is $25.7M |
| Is Pharma Equity Group profitable? | Yes, Pharma Equity Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
